Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
Disorders of Hemostasis01:24

Disorders of Hemostasis

881
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
881
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

60
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
60
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

947
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
947

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus and Associated with Lower 24-Hour Blood Pressure.

Frontiers in lupus·2026
Same author

Albuminuria Changes as a surrogate endpoint in <i>Apolipoprotein L1</i> Mediated Kidney Disease in Vanderbilt BioVU and the Million Veteran Program.

medRxiv : the preprint server for health sciences·2026
Same author

Reframing AI for Rare Disease Recognition.

Research square·2026
Same author

ImmuSeeker: deep mining of immune-related gene family signatures through lineage reconstruction.

Genome biology·2026
Same author

A Mendelian randomization-based drug repurposing pipeline: application to lipid traits and coronary artery disease.

medRxiv : the preprint server for health sciences·2026
Same author

Association of Clonal Hematopoiesis With Incident, Late-Onset, Seropositive Rheumatoid Arthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Related Experiment Video

Updated: Jun 28, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K

Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban.

Wayne A Ray1, Cecilia P Chung2,3, C Michael Stein4,5

  • 1Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.

JAMA
|April 15, 2024
PubMed
Summary
This summary is machine-generated.

Diltiazem use in atrial fibrillation patients on apixaban or rivaroxaban is linked to a higher risk of serious bleeding compared to metoprolol. This risk is especially pronounced with higher diltiazem doses.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

3.5K

Related Experiment Videos

Last Updated: Jun 28, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

3.5K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Atrial fibrillation (AF) management often involves anticoagulants like apixaban and rivaroxaban.
  • Diltiazem, a calcium channel blocker, is frequently used for ventricular rate control in AF patients.
  • Diltiazem can inhibit the metabolism of certain anticoagulants, potentially increasing bleeding risk.

Purpose of the Study:

  • To compare the risk of serious bleeding in new users of apixaban or rivaroxaban with AF.
  • To evaluate the association between diltiazem or metoprolol use and bleeding events in these patients.

Main Methods:

  • Retrospective cohort study of Medicare beneficiaries (≥65 years) with AF initiating apixaban or rivaroxaban.
  • Comparison of bleeding risk between patients also starting diltiazem versus metoprolol.
  • Follow-up for up to 365 days, with adjusted hazard ratios (HRs) and rate differences (RDs) using overlap weighting.

Main Results:

  • Diltiazem use was associated with an increased risk of the primary composite outcome (bleeding hospitalization/death) compared to metoprolol (RD: 10.6/1000 PY; HR: 1.21).
  • Higher diltiazem doses (>120 mg/d) showed a greater risk for the primary outcome (RD: 15.1/1000 PY; HR: 1.29) and major ischemic or hemorrhagic events (HR: 1.14).
  • No significant differences in ischemic stroke/systemic embolism risk were observed between groups.

Conclusions:

  • In AF patients on apixaban or rivaroxaban, diltiazem is associated with a higher risk of serious bleeding than metoprolol.
  • The increased bleeding risk with diltiazem is dose-dependent, particularly evident at doses exceeding 120 mg/d.
  • These findings highlight the importance of considering drug interactions and patient-specific risks when prescribing diltiazem with novel oral anticoagulants.